OGSIVEO (nirogacestat) is an oral medication classified as a gamma-secretase inhibitor, which plays a role in modulating the Notch signaling pathway. This drug has been approved by the U.S. FDA for the treatment of desmoid tumors in adults who exhibit disease progression and require systemic intervention. The active compound, nirogacestat, works by inhibiting gamma-secretase, a protease involved in the activation of Notch receptors. By blocking this pathway, OGSIVEO helps to reduce tumor proliferation and progression.

Approved in 2023, OGSIVEO is available in tablet form, with dosages of 50 mg, 100 mg, and 150 mg. The recommended dosage for patients is 150 mg taken twice daily until disease progression occurs or unacceptable toxicity is observed. This regimen ensures the drug's efficacy while minimizing the risk of adverse effects. It is crucial to follow the prescribed dose to maintain optimal therapeutic outcomes while managing potential side effects effectively.